- Home
- NVT vs PODD Comparison
NVT vs PODD Comparison
Compare NVT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVT | PODD |
|---|---|---|
| Founded | 1903 | 2000 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4B | 21.0B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NVT | PODD |
|---|---|---|
| Price | $112.38 | $256.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $107.58 | ★ $367.32 |
| AVG Volume (30 Days) | ★ 1.9M | 915.9K |
| Earning Date | 02-06-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ 6.36 | N/A |
| EPS | ★ 3.64 | 3.45 |
| Revenue | ★ $3,578,600,000.00 | $2,521,800,000.00 |
| Revenue This Year | $28.74 | $32.55 |
| Revenue Next Year | $15.01 | $20.47 |
| P/E Ratio | ★ $62.77 | $74.13 |
| Revenue Growth | 21.54 | ★ 27.11 |
| 52 Week Low | $41.71 | $230.05 |
| 52 Week High | $117.52 | $354.88 |
Technical Indicators
Market Signals| Indicator | NVT | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 57.54 | 24.97 |
| Support Level | $109.26 | $265.78 |
| Resistance Level | $117.00 | $288.98 |
| Average True Range (ATR) | 3.66 | 8.64 |
| MACD | 0.51 | -2.40 |
| Stochastic Oscillator | 69.76 | 6.35 |
Price Performance
Historical ComparisonAbout NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.